IQAI Software Chosen for Quantitative Accuracy and Automation - Seite 2

"We have been using IB quantitative perfusion imaging for over a year at our main cancer center, and the information has been invaluable to us in determining brain tumor treatment planning and follow-up," said Dr. Matthew Dobbs, a radiologist at EAMC. "When the radiation oncologists at one of our hospitals requested MR perfusion, we immediately recommended purchasing IB software based on our positive experiences."

For further information, please contact:

IQ-AI Limited
Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda
Tel: [phone]

Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: [phone]

About Imaging Biometrics, LLC

Imaging Biometrics®, a subsidiary of IQ-AI Limited (LON: IQAI) (OTCQB: IQAIF), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

Safe Harbor Statement

This press release includes statements that may constitute forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," or the negative of these words and/or similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. For example, statements about future revenues and the Company's ability to fund its operations and contractual obligations are forward looking and subject to risks. Several important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to, the inability to raise capital to support the Company through its growth stage, the Company's inability to generate projected sales and trade relations between the United States and China. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Investor Relations Contact:

Michael Porter, President
Porter, LeVay & Rose, Inc.
Tel: [phone]
[e-mail]

SOURCE: IQ AI Ltd.

View source version on accesswire.com:
https://www.accesswire.com/664772/IQAI-Software-Chosen-for-Quantitativ ...